Docor International Management

Docor International Management is the Israeli venture arm of the Van Leer Group Foundation, deploying patient capital into life sciences, biotech, and advanced medical hardware. The Tel Aviv-based firm is structured to take longer-horizon bets that would not fit a standard ten-year venture clock, which suits founders building regulated devices, novel biology, or hardware-heavy diagnostics. The investor type is venture, but the foundation backing means decision-making is less driven by quarterly fund pressure than at a typical sector-agnostic VC.

Reported stages are Series A and Series B, with check sizes in the $1 million to $5 million range. Healthcare sub-verticals listed are medical devices and biotech. The record does not name specific portfolio companies, but the firm is part of the broader Israeli medtech ecosystem and would likely co-invest with local life sciences specialists. Deployment is concentrated in Israel.

Founders should approach Docor as a potential later Series A or Series B participant rather than a first-money lead. Pre-seed or seed-stage healthcare AI teams without device or biology depth are unlikely to fit the patient-capital framing. Teams that benefit most are those with clinical proof points, regulatory pathways already identified, and a need for an investor that tolerates long timelines to revenue. Israeli incorporation or a strong Israeli operating presence will materially help the conversation.